Elevai Labs Inc. Subsidiary, Elevai Skincare to Debut Upcoming New Product Line at The Aesthetic Show 2024
2024年6月26日 - 10:00PM
ELEVAI LABS, INC., (NASDAQ: ELAB) a pioneering force in
medical aesthetics, is excited to announce Elevai
Skincare’s participation in The Aesthetic Show, taking place on
June 27-30, 2024 at the Wynn Las Vegas. The company will be
showcasing its latest advancements at Booth #511 and unveiling the
next generation of its groundbreaking stem cell exosome products.
Jordan R. Plews, PhD, the CEO and Co-Founder of Elevai Skincare,
will lead a highly anticipated presentation to introduce an
innovative new product line. Joining Dr. Plews will be
distinguished guest speaker Keshav Singh, PhD, a renowned scientist
and inventor of one of the key active ingredients used in Elevai's
new products.
Event Details:
- Date: June 28,
2024
- Location: The Aesthetic Show, Las Vegas
- Booth Number: 511
- Presentation Time:
3:30 PM
About Jordan R. Plews, PhD: Dr. Jordan R. Plews
is the Co-founder and CEO of Elevai Skincare. He completed his
postdoctoral and business school training at Stanford University
and holds degrees in Biochemical Engineering & Bioprocess
Development, and Stem Cell Research & Molecular Biology from
the UK.
His research has been widely published in respected journals,
including Nature Methods and the Journal of Cellular and Molecular
Medicine. Dr. Plews has a distinguished career in stem cells and
regenerative medicine, focusing on stem cell-based solutions for
injury and degenerative diseases, before pivoting into
aesthetics.
About Keshav Singh, PhD: Dr. Singh is one of
the world’s top five mitochondrial scientists, with time spent at
Harvard, Johns Hopkins, Roswell Park Cancer Institute, and now
Harbert Professor of Genetics and Director of the Cancer Genetics
Program at UAB. He Co-Founded Yuva Biosciences, a regenerative
medicine company that is developing the next generation of
therapeutics to target aging and related illnesses through
ground-breaking mitochondrial science Dr. Keshav also founded the
journal Mitochondrion and the Mitochondria Research and Medicine
Society, and has authored over 100 publications and 3 books.
About Elevai Labs, Inc.
Elevai Labs Inc. (NASDAQ: ELAB) specializes in
medical aesthetics and biopharmaceutical drug development, focusing
on innovations for skin aesthetics and treatments tied to obesity
and metabolic health. Driven by a commitment to scientific
research, we aim to transform personal health and beauty. For more
information, please visit www.elevailabs.com.
About Elevai Skincare
Elevai Skincare Inc., an Elevai Labs company, is a medical
aesthetics company developing and commercializing cutting-edge
physician-dispensed skin and hair care applications. Elevai
develops cosmetic products for the physician-dispensed market, with
a focus on leveraging novel proprietary science-backed
technologies, including its stem cell exosome technology
Forward-Looking Statements
Statements contained in this press release
regarding matters that are not historical facts are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended. Words such as
“believes,” “expects,” “plans,” “potential,” “would” and “future”
or similar expressions such as “look forward” are intended to
identify forward-looking statements. Although the Company believes
that the expectations expressed in these forward-looking statements
are reasonable, it cannot assure you that such expectations will
turn out to be correct, and the Company cautions investors that
actual results may differ materially from the anticipated results.
These and other risks are described more fully in Elevai’s filings
with the Securities and Exchange Commission (“SEC”), including the
“Risk Factors” section of the Company’s Annual Report on Form 10-K
for the year ended December 31, 2023, filed with the SEC on March
29, 2024, and its other documents subsequently filed with or
furnished to the SEC. All forward-looking statements contained in
this press release speak only as of the date on which they were
made. Except to the extent required by law, the Company undertakes
no obligation to update such statements to reflect events that
occur or circumstances that exist after the date on which they were
made.
Media Contact
Makenzie Mann
contact@elevailabs.com
Investor Relations
IR@elevailabs.com
Elevai Labs (NASDAQ:ELAB)
過去 株価チャート
から 8 2024 まで 9 2024
Elevai Labs (NASDAQ:ELAB)
過去 株価チャート
から 9 2023 まで 9 2024